Effect of Hepatic Impairment on the Pharmacokinetics of Levomilnacipran Following a Single Oral Dose of a Levomilnacipran Extended-Release Capsule in Human Participants

• Published in: Clinical drug investigation Vol. 34; no. 5; pp. 351 - 359
• Main Authors: Chen, Laishun, Boinpally, Ramesh, Greenberg, William M., Wangsa, Julie, Periclou, Antonia, Ghahramani, Parviz
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.05.2014; Springer Nature B.V
• Subjects: Administration, Oral; Adolescent; Adult; Aged; Capsules; Case-Control Studies; Cyclopropanes - administration & dosage; Cyclopropanes - pharmacokinetics; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Internal Medicine; Liver Diseases - physiopathology; Male; Medicine; Medicine & Public Health; Middle Aged; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Young Adult; Healthy Participant; Milnacipran; Hepatic Impairment; Major Depressive Disorder

Background and Objectives Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor with greater potency for the reuptake inhibition of norepinephrine than of serotonin, approved in the USA for the treatment of major depressive disorder (MDD) in adults. Methods A single-dose, open-label,...